RG 3487

Drug Profile

RG 3487

Alternative Names: MEM3454; R1589; R3487; RG3487; RO5313534

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Memory Pharmaceuticals; Roche
  • Developer Roche
  • Class Antidementias; Antipsychotics; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Schizophrenia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 13 Nov 2010 Preclinical pharmacodynamics data presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010)
  • 21 Oct 2009 Pharmacodynamics & pharmacokinetics data from preclinical trials in Alzheimer's disease presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 24 Dec 2008 Memory initiates enrolment in a phase II trial for Schizophrenia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top